In Wake of 'Flawed' GAO Report, Consumer Genomics Firms Call for Regulatory Plan for DTC Industry

Jul 28, 2010

Premium

Consumer genomics firms that were the subject of last week's damaging Government Accountability Office investigation into their practices went on the offensive this week and accused the federal agency's report of being "flawed," "misleading," and "slanderous."

At the same time, Navigenics, 23andMe, and Decode Genetics all welcomed greater regulatory oversight for the nascent industry and vowed to work with the US Food and Drug Administration to develop standards for their offerings.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Menu